Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
6 drugs in development
By Therapeutic Area
top 2
R&D Momentum
96/100
Pipeline Velocity
76/100
Trial Completion Rate
67/100
Pipeline Concentration
39/100
Pipeline Freshness
74/100
Strategic Signals
Activity
Last 14 days
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
Natural History of Familial Dysautonomia
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
Measuring Improvement in the Quality of Emergency Department-initiated Treatment for Opioid Use Disorders Using Observation
Medial Unloader Brace Impact on Clinical Outcomes Following Meniscus Repair
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
Time Restricted Eating for WeIght LoSs MainTenance-2 (TWIST-2): A Single-site, 2-arm Randomized Clinical Trial in Adults With Recent Weight Loss
Feasibility of a New Method Named Napoleon to Measure Gastrojejunal Anastomosis in Gastric Bypass Patients With Weight Regain
Effects of Implementing a Post-surgical Dietary and Lifestyle Protocol on Uterine Fibroid Recurrence
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)